Lyell Immunopharma (LYEL) Equity Average (2020 - 2026)

Lyell Immunopharma's Equity Average history runs 7 years deep, the most recent figure standing at $260.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 27.45% year-over-year to $260.9 million; the TTM figure through Mar 2026 stood at $260.9 million (down 27.45% YoY), while the FY2025 annual figure was $315.5 million, down 39.19% from the prior year.
• Equity Average came in at $260.9 million for Q1 2026 at Lyell Immunopharma, down from $288.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $905.5 million in Q1 2022 to a low of $260.9 million in Q1 2026.
• A 5-year average of $598.4 million and a median of $629.1 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average surged 389.04% in 2022 and sank 45.67% in 2025, its largest moves.
• Lyell Immunopharma's Equity Average stood at $826.6 million in 2022, then decreased by 18.19% to $676.3 million in 2023, then sank by 32.46% to $456.8 million in 2024, then plunged by 36.8% to $288.7 million in 2025, then slipped by 9.61% to $260.9 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $260.9 million, $288.7 million, and $314.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison